Uric acid within the "normal" range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
10 2019
Historique:
received: 07 02 2019
revised: 07 06 2019
accepted: 13 06 2019
pubmed: 5 8 2019
medline: 20 2 2020
entrez: 5 8 2019
Statut: ppublish

Résumé

Increased uric acid levels correlate with cardiovascular disease and cardiovascular/overall mortality. To identify a uric acid threshold above which cardiovascular mortality rises, we studied the relationship between uric acid concentration and overall/cardiovascular mortality. We analyzed data from the InCHIANTI study, a cohort study of Italian community-dwelling people with 9 years of follow-up. We selected a sample of 947 individuals over 64 years of age, free from cardio-cerebrovascular disease and with available uric acid measurement at baseline. The sample was divided according to plasma uric acid tertiles. The Hazard ratio (HR) for mortality was calculated by multivariate Cox proportional hazard model. Mean age of participants was 75.3 ± 7.3 years; the mean value of uric acid was 5.1 ± 1.4 mg/dl. Over 9-years of follow-up, 342 (36.1%) participants died, 143 deaths (15.1%) were due to cardiovascular disease. Subjects with higher uric acid concentrations presented a higher cardiovascular mortality [II (4.6-5.5 mg/dl) vs I (1.8-4.5 mg/dl) tertile HR: 1.98, 95%C.I. 1.22-3.23; III (≥5.6 mg/dl) vs I tertile HR: 1.87, 95%C.I. 1.13-3.09]. We found a non-linear association between uric acid concentrations and cardiovascular mortality with the lowest mortality for values of about 4.1 mg/dl and a significant risk increment for values above 4.3 mg/dl. In community-dwelling older individuals free from cardio-cerebrovascular events, the lowest 9-year cardiovascular mortality was observed for uric acid values far below current target values. If confirmed, these data might represent the background for investigating the efficacy of uric acid levels reduction in similar populations.

Sections du résumé

BACKGROUND AND AIMS
Increased uric acid levels correlate with cardiovascular disease and cardiovascular/overall mortality. To identify a uric acid threshold above which cardiovascular mortality rises, we studied the relationship between uric acid concentration and overall/cardiovascular mortality.
METHODS AND RESULTS
We analyzed data from the InCHIANTI study, a cohort study of Italian community-dwelling people with 9 years of follow-up. We selected a sample of 947 individuals over 64 years of age, free from cardio-cerebrovascular disease and with available uric acid measurement at baseline. The sample was divided according to plasma uric acid tertiles. The Hazard ratio (HR) for mortality was calculated by multivariate Cox proportional hazard model. Mean age of participants was 75.3 ± 7.3 years; the mean value of uric acid was 5.1 ± 1.4 mg/dl. Over 9-years of follow-up, 342 (36.1%) participants died, 143 deaths (15.1%) were due to cardiovascular disease. Subjects with higher uric acid concentrations presented a higher cardiovascular mortality [II (4.6-5.5 mg/dl) vs I (1.8-4.5 mg/dl) tertile HR: 1.98, 95%C.I. 1.22-3.23; III (≥5.6 mg/dl) vs I tertile HR: 1.87, 95%C.I. 1.13-3.09]. We found a non-linear association between uric acid concentrations and cardiovascular mortality with the lowest mortality for values of about 4.1 mg/dl and a significant risk increment for values above 4.3 mg/dl.
CONCLUSION
In community-dwelling older individuals free from cardio-cerebrovascular events, the lowest 9-year cardiovascular mortality was observed for uric acid values far below current target values. If confirmed, these data might represent the background for investigating the efficacy of uric acid levels reduction in similar populations.

Identifiants

pubmed: 31377184
pii: S0939-4753(19)30247-9
doi: 10.1016/j.numecd.2019.06.018
pmc: PMC6744329
mid: NIHMS1536257
pii:
doi:

Substances chimiques

Biomarkers 0
Uric Acid 268B43MJ25

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1061-1067

Subventions

Organisme : NIA NIH HHS
ID : N01 AG050002
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AG001050-05
Pays : United States

Informations de copyright

Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Références

Nephrol Dial Transplant. 2004 Feb;19(2):457-62
pubmed: 14736974
Angiology. 2007 Aug-Sep;58(4):450-7
pubmed: 17875958
J Am Geriatr Soc. 2000 Dec;48(12):1618-25
pubmed: 11129752
QJM. 2013 Jul;106(7):647-58
pubmed: 23564632
Arthritis Res Ther. 2010;12(6):223
pubmed: 21205285
BMJ. 2008 Feb 9;336(7639):309-12
pubmed: 18244959
Stroke. 2006 Jun;37(6):1503-7
pubmed: 16675740
Int J Mol Med. 2015 May;35(5):1347-54
pubmed: 25813103
Int J Epidemiol. 1997;26 Suppl 1:S15-25
pubmed: 9126530
J Am Geriatr Soc. 2013 Mar;61(3):319-26
pubmed: 23496291
Circ J. 2010 Feb;74(2):213-20
pubmed: 20065609
Free Radic Biol Med. 2011 Jul 1;51(1):179-84
pubmed: 21554948
J Am Soc Nephrol. 2005 Dec;16(12):3553-62
pubmed: 16251237
Int J Cardiol. 2016 Jun 15;213:20-2
pubmed: 26386814
Electrolyte Blood Press. 2014 Jun;12(1):1-6
pubmed: 25061467
Clin J Am Soc Nephrol. 2011 Aug;6(8):1887-94
pubmed: 21784838
Circulation. 2001 Nov 13;104(20):2407-11
pubmed: 11705816
J Hypertens. 2015 Sep;33(9):1729-41; discussion 1741
pubmed: 26136207
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Arthritis Care Res (Hoboken). 2010 Feb;62(2):170-80
pubmed: 20191515
BMC Nephrol. 2013 Jul 29;14:164
pubmed: 23895142
BMC Musculoskelet Disord. 2013 Aug 30;14:258
pubmed: 24000893
J Am Geriatr Soc. 2015 Sep;63(9):1829-36
pubmed: 26277576
Heart. 2013 Jun;99(11):759-66
pubmed: 23343689
Ann Rheum Dis. 2016 Apr;75(4):755-62
pubmed: 25649144
Atherosclerosis. 2013 Nov;231(1):61-8
pubmed: 24125412
J Cardiovasc Transl Res. 2014 Feb;7(1):9-18
pubmed: 24327329
Nephron. 1976;16(1):31-41
pubmed: 1244564
Rheumatol Int. 2014 Jan;34(1):101-9
pubmed: 24026528
Kidney Int. 2004 Mar;65(3):1041-9
pubmed: 14871425
J Am Coll Cardiol. 2011 Aug 16;58(8):820-8
pubmed: 21835317
Circ J. 2013;77(8):2043-9
pubmed: 23676888
Am J Epidemiol. 1985 Jan;121(1):11-8
pubmed: 3964986
Sci Rep. 2016 Jan 27;6:19520
pubmed: 26814153
J Clin Biochem Nutr. 2013 Jan;52(1):38-42
pubmed: 23341696

Auteurs

Gloria Brombo (G)

Department of Medical Sciences, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Italy. Electronic address: g.brombo@gmail.com.

Francesco Bonetti (F)

Department of Medical Sciences, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Italy.

Stefano Volpato (S)

Department of Medical Sciences, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Italy.

Mario L Morieri (ML)

Department of Medical Sciences, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Italy.

Ettore Napoli (E)

Department of Medical Sciences, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Italy.

Stefania Bandinelli (S)

Geriatric Rehabilitation Unit, Tuscany Regional Health Agency, Florence, Italy.

Antonio Cherubini (A)

Geriatrics, IRCCS-INRCA, Ancona, Italy.

Marcello Maggio (M)

Department of Clinical and Experimental Medicine, Section of Geriatrics, University of Parma, Italy.

Jack Guralnik (J)

Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, USA.

Luigi Ferrucci (L)

Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, NIH, Baltimore, USA.

Giovanni Zuliani (G)

Department of Morphology, Surgery and Experimental Medicine, Section of Internal and Cardiorespiratory Medicine, University of Ferrara, Ferrara, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH